» Articles » PMID: 31152791

Lipidomic Biomarkers and Mechanisms of Lipotoxicity in Non-alcoholic Fatty Liver Disease

Overview
Date 2019 Jun 2
PMID 31152791
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease worldwide (about 25% of the general population) and 3-5% of patients develop non-alcoholic steatohepatitis (NASH), characterized by hepatocytes damage, inflammation and fibrosis, which increase the risk of developing liver failure, cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD, particularly the mechanisms whereby a minority of patients develop a more severe phenotype, is still incompletely understood. In this review we examine the available literature on initial mechanisms of hepatocellular damage and inflammation, deriving from toxic effects of excess lipids. Accumulating data indicate that the total amount of triglycerides stored in the liver cells is not the main determinant of lipotoxicity and that specific lipid classes act as damaging agents. These lipotoxic species affect the cell behavior via multiple mechanisms, including activation of death receptors, endoplasmic reticulum stress, modification of mitochondrial function and oxidative stress. The gut microbiota, which provides signals through the intestine to the liver, is also reported to play a key role in lipotoxicity. Finally, we summarize the most recent lipidomic strategies utilized to explore the liver lipidome and its modifications in the course of NALFD. These include measures of lipid profiles in blood plasma and erythrocyte membranes that can surrogate to some extent lipid investigation in the liver.

Citing Articles

Aspirin Eugenol Ester Alleviates Energy Metabolism Disorders by Reducing Oxidative Damage and Inflammation in the Livers of Broilers Under High-Stocking-Density Stress.

Guo C, Zhang Y, Bai D, Zhen W, Ma P, Wang Z Int J Mol Sci. 2025; 26(5).

PMID: 40076504 PMC: 11899955. DOI: 10.3390/ijms26051877.


Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease.

Hegazy D, Mohamed F, Mahmoud S, El Deeb N, Elyamany A, Elgendi A Clin Exp Hepatol. 2025; 10(2):79-89.

PMID: 39845348 PMC: 11748224. DOI: 10.5114/ceh.2024.139983.


Ellagic Acid Modulates Necroptosis, Autophagy, Inflammations, and Stress to Ameliorate Nonalcoholic Liver Fatty Disease in a Rat Model.

Li Z, Li J, He S, Chen J, Deng C, Duan J Food Sci Nutr. 2025; 13(1):e4694.

PMID: 39830906 PMC: 11742184. DOI: 10.1002/fsn3.4694.


Purinergic P2X7 receptor mediates hyperoxia-induced injury in pulmonary microvascular endothelial cells via NLRP3-mediated pyroptotic pathway.

Zeng W, Deng Z, Li H, Gao S, Ju R Open Med (Wars). 2024; 19(1):20241097.

PMID: 39655049 PMC: 11627065. DOI: 10.1515/med-2024-1097.


Adrenic acid: A promising biomarker and therapeutic target (Review).

Wang Z, Gao H, Ma X, Zhu D, Zhao L, Xiao W Int J Mol Med. 2024; 55(2).

PMID: 39575474 PMC: 11611323. DOI: 10.3892/ijmm.2024.5461.